Dynacure to Present Disease Progression Model and Natural History Study Data at the 25th Annual Congress of the World Muscle Society (WMS25)siteadmin2020-11-07T02:09:54-08:00September 28, 2020|
Dynacure Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for DYN101 for Myotubular and Centronuclear Myopathies (CNM)siteadmin2020-11-07T02:12:27-08:00July 30, 2020|
Dynacure Announces Presentations at Upcoming Investor Conferencessiteadmin2020-11-07T02:13:48-08:00July 28, 2020|
Dynacure Announces Presentation at Jefferies Virtual Global Healthcare Conferencesiteadmin2020-11-07T02:15:15-08:00May 27, 2020|
Dynacure Announces First Patient Dosed in Phase 1 / 2 ‘UNITE-CNM’ Study of DYN101 for the Treatment of Myotubular and Centronuclear Myopathies (CNM)siteadmin2020-11-07T02:19:18-08:00March 5, 2020|
Dynacure to Present at 40th Annual Cowen Healthcare Conferencesiteadmin2020-11-07T02:20:55-08:00February 26, 2020|
Dynacure’s Chief Scientific Officer, Dr. Belinda Cowling, Receives Irène Joliot-Curie Prize for Women in Business and Technologysiteadmin2020-11-07T02:22:26-08:00November 27, 2019|
Dynacure Presents New Preclinical Results on Muscle Targeting with Antisense Oligonucleotides at the 24th Annual International Congress of the World Muscle Societysiteadmin2020-11-07T02:27:05-08:00October 2, 2019|
Dynacure Wins Ernst & Young’s Prix “Born Global” Awardsiteadmin2020-11-07T02:28:09-08:00September 18, 2019|
Community